45 related articles for article (PubMed ID: 10830713)
1. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation.
Mukherjee S; Haenel T; Himbeck R; Scott B; Ramshaw I; Lake RA; Harnett G; Phillips P; Morey S; Smith D; Davidson JA; Musk AW; Robinson B
Cancer Gene Ther; 2000 May; 7(5):663-70. PubMed ID: 10830713
[TBL] [Abstract][Full Text] [Related]
2. Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus.
Hill C; Grundy M; Bau L; Wallington S; Balkaran J; Ramos V; Fisher K; Seymour L; Coussios C; Carlisle R
Mol Ther Oncolytics; 2021 Jun; 21():47-61. PubMed ID: 33869742
[TBL] [Abstract][Full Text] [Related]
3. Redirecting anti-Vaccinia virus T cell immunity for cancer treatment by AAV-mediated delivery of the VV B8R gene.
Cao D; Song Q; Li J; Chard Dunmall LS; Jiang Y; Qin B; Wang J; Guo H; Cheng Z; Wang Z; Lemoine NR; Lu S; Wang Y
Mol Ther Oncolytics; 2022 Jun; 25():264-275. PubMed ID: 35615262
[TBL] [Abstract][Full Text] [Related]
4. A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma.
Sterman DH; Haas A; Moon E; Recio A; Schwed D; Vachani A; Katz SI; Gillespie CT; Cheng G; Sun J; Papasavvas E; Montaner LJ; Heitjan DF; Litzky L; Friedberg J; Culligan M; June CH; Carroll RG; Albelda SM
Am J Respir Crit Care Med; 2011 Dec; 184(12):1395-9. PubMed ID: 21642245
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions.
Sterman DH; Recio A; Haas AR; Vachani A; Katz SI; Gillespie CT; Cheng G; Sun J; Moon E; Pereira L; Wang X; Heitjan DF; Litzky L; June CH; Vonderheide RH; Carroll RG; Albelda SM
Mol Ther; 2010 Apr; 18(4):852-60. PubMed ID: 20068553
[TBL] [Abstract][Full Text] [Related]
6. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses.
Sterman DH; Recio A; Carroll RG; Gillespie CT; Haas A; Vachani A; Kapoor V; Sun J; Hodinka R; Brown JL; Corbley MJ; Parr M; Ho M; Pastan I; Machuzak M; Benedict W; Zhang XQ; Lord EM; Litzky LA; Heitjan DF; June CH; Kaiser LR; Vonderheide RH; Albelda SM; Kanther M
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4456-66. PubMed ID: 17671130
[TBL] [Abstract][Full Text] [Related]
7. How Our Continuing Studies of the Pre-clinical Inbred Mouse Models of Mesothelioma Have Influenced the Development of New Therapies.
Robinson BWS; Redwood AJ; Creaney J
Front Pharmacol; 2022; 13():858557. PubMed ID: 35431929
[TBL] [Abstract][Full Text] [Related]
8. High Oncolytic Activity of a Double-Deleted Vaccinia Virus Copenhagen Strain against Malignant Pleural Mesothelioma.
Delaunay T; Nader J; Grard M; Farine I; Hedwig V; Foloppe J; Blondy T; Violland M; Pouliquen D; Grégoire M; Boisgerault N; Erbs P; Fonteneau JF
Mol Ther Oncolytics; 2020 Sep; 18():573-578. PubMed ID: 32995481
[TBL] [Abstract][Full Text] [Related]
9. Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses.
Nguyen T; Avci NG; Shin DH; Martinez-Velez N; Jiang H
Cancers (Basel); 2018 May; 10(6):. PubMed ID: 29857493
[TBL] [Abstract][Full Text] [Related]
10. Potential of oncolytic viruses in the treatment of multiple myeloma.
Bartee E
Oncolytic Virother; 2017; 7():1-12. PubMed ID: 29503813
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic Viral Therapy for Mesothelioma.
Pease DF; Kratzke RA
Front Oncol; 2017; 7():179. PubMed ID: 28884088
[TBL] [Abstract][Full Text] [Related]
12. Combined expression of miR-34a and Smac mediated by oncolytic vaccinia virus synergistically promote anti-tumor effects in Multiple Myeloma.
Lei W; Wang S; Yang C; Huang X; Chen Z; He W; Shen J; Liu X; Qian W
Sci Rep; 2016 Aug; 6():32174. PubMed ID: 27552933
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic virotherapy for human malignant mesothelioma: recent advances.
Boisgerault N; Achard C; Delaunay T; Cellerin L; Tangy F; Grégoire M; Fonteneau JF
Oncolytic Virother; 2015; 4():133-40. PubMed ID: 27512676
[TBL] [Abstract][Full Text] [Related]
14. The "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment.
Nelson D; Fisher S; Robinson B
J Immunol Res; 2014; 2014():789069. PubMed ID: 24955376
[TBL] [Abstract][Full Text] [Related]
15. Antiglioma oncolytic virotherapy: unattainable goal or a success story in the making?
Dey M; Auffinger B; Lesniak MS; Ahmed AU
Future Virol; 2013 Jul; 8(7):675-693. PubMed ID: 24910708
[TBL] [Abstract][Full Text] [Related]
16. A potential therapeutic strategy for malignant mesothelioma with gene medicine.
Tada Y; Shimada H; Hiroshima K; Tagawa M
Biomed Res Int; 2013; 2013():572609. PubMed ID: 23484132
[TBL] [Abstract][Full Text] [Related]
17. Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies.
Haas AR; Sterman DH
Clin Chest Med; 2013 Mar; 34(1):99-111. PubMed ID: 23411061
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy for lung neoplasms.
Vachani A; Moon E; Wakeam E; Haas AR; Sterman DH; Albelda SM
Clin Chest Med; 2011 Dec; 32(4):865-85. PubMed ID: 22054892
[TBL] [Abstract][Full Text] [Related]
19. Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?
Naik JD; Twelves CJ; Selby PJ; Vile RG; Chester JD
Clin Cancer Res; 2011 Jul; 17(13):4214-24. PubMed ID: 21576084
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy for mesothelioma.
Vachani A; Moon E; Albelda SM
Curr Treat Options Oncol; 2011 Jun; 12(2):173-80. PubMed ID: 21519819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
